3-(Pyrrolidine-1-Carbonyl)Phenylboronic Acid: Reliable Building Block for Advanced Synthesis

From the perspective of a manufacturer who invests deeply in research and hands-on process optimization, there are few intermediates as versatile as 3-(Pyrrolidine-1-carbonyl)phenylboronic acid. Over the past ten years, demand for complex boronic acids has grown. This molecule in particular has carved out its place as a foundation for custom APIs and small-molecule pharmaceuticals. Before we ever scaled our batches, we tested each reaction stage and tracked the smallest changes. The end result: a product that consistently meets the high standards demanded by medicinal chemistry teams across the world.

Model and Specifications: Precision Rooted in Practice

Throughout scale-up and reproducibility studies, we saw the value of sticking to a single, verified molecular formula and a consistent specification—not just for regulatory traceability, but also for minimizing downstream headaches our clients might face. 3-(Pyrrolidine-1-carbonyl)phenylboronic acid, with CAS number 1014690-04-4, comes as a pure, easily-handled crystalline powder during synthesis. Rigorous HPLC and NMR checks along every lot tie each shipment tightly to its certificate of analysis.

Each finished batch registers purity exceeding 98.5% by HPLC, which aligns with what top chemical developers expect for use in Suzuki-Miyaura cross-couplings or for conjugate additions. Attention to low water content through vacuum drying steps keeps hydrolysis in check. Consistent melting points and fine particulate sizing make weighing and dissolution straightforward and repeatable.

Usage: Boronic Acid Functionality Unlocks Value in Drug Design

Every synthetic chemist recognizes the flexibility the boronic acid group brings. For some, the main draw centers on C–C bond construction, leveraging Suzuki-coupling under mild conditions. For others, it is the ready conversion to other derivatives—esters, amides, even acylated forms—that expands its value. We see our clients push the boundaries of the molecule’s scaffold, especially in targeted therapy development.

The pyrrolidine-1-carbonyl moiety adds extra stability and steric profile, offering a different reactivity set compared to simple phenylboronic acid. Medicinal chemistry teams have commented to us that this specific substitution creates opportunities for tuning solubility, fine-tuning hydrogen bonding interactions, and achieving fit within complex enzyme pockets. Compared to more basic boronic acids, this compound supports a wider structural diversity in heterocyclic and peptide-like settings.

In the lab, 3-(Pyrrolidine-1-carbonyl)phenylboronic acid dissolves easily into most polar organic solvents—our team tracks solubility curves in DMF, DMSO, and acetonitrile before every product release. We’ve seen success stories where clients used it to add a unique framework in kinase inhibitor candidates. Yields remain high owing to the electron-donating effect from the carbonyl-pyrrolidine substitution, which prevents deactivation of the boronate site.

What Sets This Compound Apart

Unlike core-line boronic acids that struggle in certain water-sensitive transformations, this model has shown robust behavior under aqueous and mixed solvent conditions thanks to its stabilizing side group. Our experience has shown fewer issues with protodeboronation—a nagging source of unreliability in high-throughput screens—because the adjacent amide secures electron distribution.

We’ve also heard consistent feedback from fragment-based drug discovery teams who rely on precise functional group placement. The protected nitrogen in the pyrrolidine ring enhances metabolic stability and lowers off-target reactivity. Our own pilot tests confirm that scale-up batches deliver the same single-phase crystal habit every time, ruling out the risk of polymorphic changes that sometimes hit other boronic acids.

A persistent challenge in this segment is managing boronic acid dimerization and anhydride formation. You don’t have to work around these side products in our system. Optimizing storage and packing under dry argon, combined with regularly changing the milling drum, prevents trace contamination. Several of our clients actually report that their control reactions using other vendors’ materials see up to 6% by mass impurities from these processes, leading to purification headaches.

Comparisons with Similar Products

Plenty of other boronic acids, such as 4-substituted phenylboronic acids or those with open chain alkylamide bodies, appear similar on paper. In practice, those materials display higher rates of oxidative decomposition on the bench, lower yields in stepwise coupling, or present greater batch-to-batch variation. Our technical staff has observed these issues directly using comparative runs, especially above 10-gram scales.

Another key difference arises in solubility and downstream work-up. Standard phenylboronic acid, lacking the pyrrolidine-1-carbonyl motif, requires extra base or higher temperatures to get the same dissolution and reactivity. The polarity introduced by the amide and heterocycle fits seamlessly into multistep campaigns. In medicinal chemistry terms, you gain a chance for more favorable pharmacokinetics without labor-intensive derivatization.

We keep in close contact with synthesis professionals developing kinase, protease, and GPCR modulators. Their feedback affirms the importance of differentiated molecular frameworks—especially in scaffolds like this one, which allow for further post-coupling elaboration. Orthogonal protection strategies remain open, thanks to the neutral pyrrolidine ring, which does not interfere with common deprotection or activation chemistries during late-stage synthesis.

Pathways to Improved Sourcing and Sustainable Production

Behind every kilogram of 3-(Pyrrolidine-1-carbonyl)phenylboronic acid, there’s a steady push toward process improvement. Steps like aging precursor stocks under nitrogen and refining solvent recovery contribute to fewer impurities and waste. Demand has shifted toward green chemistry—not out of marketing pressure, but real concern over process safety and cost savings.

Reducing the need for excess reagents remains a central concern. In recent campaigns, switching to more active coupling agents and real-time monitoring with HPLC allow us to keep yields high and reduce decomposition. Routine in-process controls, from raw material identity checks via FTIR to end-stage moisture analysis by KF, bring robust data to every release. The stakes are high when clients rely on kilogram lots for direct use in regulatory filings or pilot-scale manufacture.

We’ve also acted on requests for sustainability, both by tightening up our fluorinated solvent loop and switching a portion of our waste management to closed-loop recycling with solvent suppliers. That’s the kind of benefit that comes from having seen how avoided waste dramatically cuts both costs and compliance worries. Comments from client auditors reaffirm that process transparency now counts as much as price or delivery lead time.

Supporting Research, Development, and Custom Synthesis

Our client base often transitions from discovery to scale-up with the same supplier. This comes from a history of solving custom requests—not just delivering off-the-shelf products. Whether adjusting particle size distribution or supporting an unusual analytical request, our flexibility grows out of years of hands-on batch work. Medicinal chemistry and process optimization teams alike have commented that running repeatable reactions with our materials cuts down their own development risks.

Regular technical exchanges—scientist to scientist, not just sales to purchasing—allow us to refine key processes. Early discussions with therapeutic research teams led us to develop incremental improvements, such as in-batch nitrogen purging or short-path purification steps. These changes, once proven on our pilot line, get written into the standard operating procedures so that new lots always look like the original proven material.

In the custom synthesis sector, reliability counts twice. In our view, the best guarantee of reliability doesn’t come from a certificate or a marketing claim—it comes from years of direct feedback and willingness to adapt. We see the same core requests: avoid false starts, hit specifications, and document everything that matters for regulatory review. By keeping each production record and analytical trace on file, we help smooth the way for our customers to advance to their next target.

Common Customer Challenges and Solutions

Scientists working with boronic acids often face three central issues: product decomposition, solubility limitations, and unpredictable side reactions. We see these same hurdles in research literature and in client feedback. Years ago, we overhauled our synthetic route to protect the boronic group from warm stages in the process, thereby preventing unwanted byproducts.

Handling and packaging also gets close attention. Before switching to current packaging designs, we heard too many stories from colleagues about caked or hydrolyzed boronic acids arriving at the bench. A double-sealed, inert atmosphere container solved this. Now, even materials stored for several months under proper conditions arrive and dissolve as expected.

Unintended cross-reactivity—either in coupling or amidation stages—caused lost time for project teams in the past. Aligning our process to minimize free amines and avoiding excess acid ensures that our material works predictably in sensitive organometallic systems and peptide couplings. Real-world testing, not just paperwork, points out these patterns. In-house, we run each new lot through model Suzuki couplings, so we see the impact of small impurity drifts before our clients do.

We consider cost not just in price per gram, but in ease of use and risk. Rework and lost material count against savings in any procurement plan. Our focus rests on supplying an intermediate that performs reliably—no workarounds required—so project chemistry advances on schedule.

Quality Assurance: Lessons and Standards

Each batch of 3-(Pyrrolidine-1-carbonyl)phenylboronic acid receives full analytical clearance before leaving the plant. By embedding high-resolution NMR, mass spectrometry, and HPLC into our daily QC procedures, we meet specifications that outperform basic pharmacopeia requirements. These checks do not only satisfy regulatory necessity; they let our clients on the frontlines of discovery trust that this intermediate won’t introduce avoidable noise into their assays or manufacturing sequences.

Long-term customers point out how much their confidence grows from traceable, consistent certificate data linked directly to batch numbers. If a method changes or a new impurity appears, updates go out with full analytical support. In a field governed by hard deadlines and scarce opportunity, trust grows from years of getting things right—not simply following the documentation, but living up to it daily.

From AHPLC to Karl Fischer titration, each QC run builds on the experience gained with thousands of grams passing through our hands. Teams in the lab rely on these controls not because regulators require them, but because small differences become large setbacks at late stages of synthesis. We invest in this infrastructure to make our clients’ work easier and more focused.

Conclusion: Drawing From Decades of Experience

Anyone working day-to-day in pharmaceutical chemistry knows that reliable materials set the pace for innovation. Each bottle of 3-(Pyrrolidine-1-carbonyl)phenylboronic acid we produce reflects the lessons earned through tough projects, demanding clients, and a commitment to constant process improvement. The next step in molecular design or the next leap in candidate selection starts from dependable building blocks. As manufacturers, we see ourselves less as suppliers and more as collaborators, sharing both knowledge and accountability at every stage—from order to bench to clinic.

By prioritizing quality, transparency, and adaptability, we help bridge the gap between discovery and delivery. Our long-standing relationships within the research community remind us daily that new challenges will arise, calls for new derivatives will increase, and our willingness to listen and improve will distinguish us in a field where only the best survive. Proper sourcing of advanced intermediates like 3-(Pyrrolidine-1-carbonyl)phenylboronic acid makes a difference not just to chemistry, but to every new treatment and technology that follows.